Novo Nordisk AS (NYSE:NVO)
$ 106.8 0.67 (0.63%) Market Cap: 474.49 Bil Enterprise Value: 471.95 Bil PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 95/100

Q1 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript

May 09, 2023 / 12:15PM GMT
Release Date Price: $84.27 (+0.05%)
Peter Hugreffe Ankersen;S;Head of IR;Corporate VP
Novo Nordisk A

/-&

Actually, it's Pete Verdult from Citi. So welcome, everyone. On behalf of Citi, delighted to have Karsten Knudsen, Group CFO; and Martin Lange, Head of R&D; plus various members of the Novo [Nordisk] team in London for the Q1 roadshow. You all know the drill, short presentation and then straight into Q&A. A bit of housekeeping. There are microphones on each of the tables, which are on currently. So if you can all have your phones on silent and try and eat quietly and cluster less, that'll be fantastic.

So without further ado, Karsten Knudsen. Thank you.

Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board

/- -

Thanks, Pete, and thanks for the invitation and you're hosting our Novo Nordisk Q1 roadshow in the London lunch meeting in conjunction with Q1. We're bringing fantastic set of numbers. So it's great to be in London and see you all and also

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot